A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

@article{Carlin2004A5R,
  title={A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.},
  author={Christopher S Carlin and Steven R. Feldman and James G. Krueger and Alan Menter and Gerald G. Krueger},
  journal={Journal of the American Academy of Dermatology},
  year={2004},
  volume={50 6},
  pages={859-66}
}
A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis. Many consider this endpoint to be too stringent as it places potentially useful therapies at risk of failing to demonstrate efficacy. We hypothesized that a 50% reduction in the PASI score (PASI 50) represents a meaningful change in a person's life and thus is a better primary endpoint. To test this hypothesis, we analyzed PASI… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 81 extracted citations

Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.

Expert review of pharmacoeconomics & outcomes research • 2014
View 10 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…